For example, KRAS inhibition has been shown to increase the infiltration of regulatory T cells (T-regs) that suppress antitumor immunity.87,295,305 Thus, current strategies involve the selective depletion of these tumor-infiltrating T-regs through the targeting of specific cell surface markers (CD25 or CCR8).306 Direct targeting of KRAS-driven immune evasion mechanisms has also been explored. This evidence concerns the gene KRAS and neoplasm.